Use of vitamin D analogs to treat conditions related to increased oxidative stress

Abstract

A pharmaceutical composition for reducing the rate at which skin ages or for treating cancer, acne or rosacea. The composition comprises a pharmaceutically acceptable excipient in combination with 26,27-hexafluoro-1,25-dihydroxy vitamin D 3 . The composition is preferably administered topically at a concentration of about 0.0001% weight to about 0.01% weight.

The subject matter claimed is:  
     
         1 . A pharmaceutical composition for reducing the rate at which skin ages or for treating epithelial cancer, acne or rosacea, which composition comprises a pharmaceutically-acceptable excipient in combination with the compound 26,27-hexafluoro-1,25-dihydroxy vitamin D 3 .  
     
     
         2 . The composition of  claim 1  that is a topical ointment composition.  
     
     
         3 . The composition of  claim 2  wherein the compound is present in an amount of about 0.0001% weight to about 0.01% weight of the total composition.  
     
     
         4 . A method for treating acne in the skin in a human, which method comprises administering the compound 26,27-hexafluoro-1,25-dihydroxy vitamin D 3  to a human in need thereof on a daily basis in an amount sufficient to reduce the severity of the acne.  
     
     
         5 . The method of  claim 4  wherein the compound is administered by topically administering a topical, pharmaceutically-acceptable excipient in combination with the compound.  
     
     
         6 . The method of  claim 5 , wherein the topical composition is an ointment comprising about 0.0001% weight to about 0.01% weight of the compound.  
     
     
         7 . A method for treating rosacea in the skin in a human, which method comprises administering the compound 26,27-hexafluoro-1,25-dihydroxy vitamin D 3  to a human in need thereof on a daily basis in an amount sufficient to reduce the severity of the rosacea.  
     
     
         8 . The method of  claim 7  wherein the compound is administered by topically administering a topical, pharmaceutically-acceptable excipient in combination with the compound.  
     
     
         9 . The method of  claim 8 , wherein the topical composition is an ointment comprising about 0.0001% weight to about 0.01% weight of the compound.  
     
     
         10 . A method for reducing the rate at which skin of a human ages, which method comprises topically administering the compound 26,27-hexafluoro-1,25-dihydroxy vitamin D 3  to the skin of the human on a daily basis in an antioxidative amount for a time sufficient to reduce the rate of skin aging.  
     
     
         11 . The method of  claim 10  wherein the compound is administered by topically administering a topical, pharmaceutically-acceptable excipient in combination with the compound.  
     
     
         12 . The method of  claim 11 , wherein the topical composition is an ointment comprising about 0.000.1% weight to about 0.01% weight of the compound.  
     
     
         13 . A method for treating epitehlial cancer in a human, which method comprises topically administering the compound 26,27-hexafluoro-1,25-dihydroxy vitamin D 3  to the cancerous portion of the human's skin on a daily basis in an anti-cancerous amount for a time sufficient to alleviate the cancer.  
     
     
         14 . The method of  claim 13  wherein the compound is administered by topically administering a topical, pharmaceutically-acceptable excipient in combination with the compounds.  
     
     
         15 . The method of  claim 14 , wherein the topical composition is an ointment comprising about 0.000.1% weight to about 0.01% weight of the compound.  
     
     
         16 . The topical pharmaceutical composition in accordance with  claim 1  as an article of manufacture in combination with written instructions for performing the method of reducing the rate of skin aging or treating acne, rosacea or epithelia cancer.  
     
     
         17 . A process for preparing a topically-applied pharmaceutical composition, which process comprises combining the compound 26,27-hexafluoro-1,25-dihydroxy vitamin D 3  with a pharnaceutically-acceptable excipient to form a topically-applied composition useful for reducing the rate at which sin ages or for treating acne, rosacea or cancer.  
     
     
         18 . The process of  claim 17 , wherein the topically-applied composition is an ointment comprising about 0.0001% weight to about 0.01% weight of the compound.